Division of Hospital Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA.
Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Diego, La Jolla, CA.
Hepatology. 2021 Sep;74(3):1509-1522. doi: 10.1002/hep.31835. Epub 2021 Jun 2.
Chronic liver diseases (CLD) affect approximately 2% of the U.S. population and are associated with substantial burden of hospitalization and costs. We estimated the national burden and consequences of financial hardship from medical bills in individuals with CLD.
Using the National Health Interview Survey from 2014 to 2018, we identified individuals with self-reported CLD. We used complex weighted survey analysis to obtain national estimates of financial hardship from medical bills and other financial toxicity measures (eg, cost-related medication nonadherence, personal and/or health care-related financial distress, food insecurity). We evaluated the association of financial hardship from medical bills with unplanned health care use and work productivity, accounting for differences in age, sex, race/ethnicity, insurance, income, education, and comorbidities. Of the 3,666 (representing 5.3 million) U.S. adults with CLD, 1,377 (representing 2 million [37%, 95% CI: 35%-39%]) reported financial hardship from medical bills, including 549 (representing 740,000 [14%, 95% CI: 13%-16%]) who were unable to pay medical bills at all. Adults who were unable to pay medical bills had 8.4-times higher odds of cost-related medication nonadherence (adjusted OR [aOR], 8.39 [95% CI, 5.72-12.32]), 6.3-times higher odds of financial distress (aOR, 6.33 [4.44-9.03]), and 5.6-times higher odds of food insecurity (aOR, 5.59 [3.74-8.37]), as compared to patients without financial hardship from medical bills. Patients unable to pay medical bills had 1.9-times higher odds of emergency department visits (aOR, 1.85 [1.33-2.57]) and 1.8-times higher odds of missing work due to disease (aOR, 1.83 [1.26-2.67]).
One in 3 adults with CLD experience financial hardship from medical bills, and frequently experience financial toxicity and unplanned healthcare use. These financial determinates of health have important implications in the context of value-based care.
慢性肝病(CLD)影响了美国约 2%的人口,与大量住院和医疗费用负担相关。我们评估了 CLD 患者的医疗费用带来的经济困难负担和后果。
我们使用了 2014 年至 2018 年的全国健康访谈调查(National Health Interview Survey),识别出报告有 CLD 的个体。我们使用复杂的加权调查分析来获取全国范围内因医疗费用而面临经济困难的估计值和其他财务毒性指标(例如,与费用相关的药物不依从、个人和/或医疗相关的经济困境、食物不安全)。我们评估了医疗费用带来的经济困难与非计划性医疗保健使用和工作生产力之间的关联,同时考虑了年龄、性别、种族/民族、保险、收入、教育和合并症的差异。在 3666 名(代表 530 万人)CLD 美国成年人中,有 1377 名(代表 200 万人[37%,95%CI:35%-39%])报告医疗费用带来了经济困难,其中 549 名(代表 74 万人[14%,95%CI:13%-16%])完全无法支付医疗费用。无法支付医疗费用的成年人与费用相关的药物不依从的可能性高 8.4 倍(调整后的比值比[OR],8.39[95%CI,5.72-12.32]),经济困境的可能性高 6.3 倍(OR,6.33[4.44-9.03]),食物不安全的可能性高 5.6 倍(OR,5.59[3.74-8.37]),而不是没有医疗费用经济困难的患者。无法支付医疗费用的患者因急诊就诊的可能性高 1.9 倍(OR,1.85[1.33-2.57]),因病缺勤的可能性高 1.8 倍(OR,1.83[1.26-2.67])。
每 3 名 CLD 成年人中就有 1 人因医疗费用而面临经济困难,并且经常经历财务毒性和非计划性医疗保健使用。这些健康的经济决定因素在基于价值的医疗保健中具有重要意义。